Teva Pharmaceutical profit, revenue rise in fourth quarter
JERUSALEM, Jan 28 (Reuters) - Teva Pharmaceutical Industries TEVA.TA reported on Wednesday a higher-than-expected rise in fourth-quarter profit, boosted by sales of its branded drugs as well as a milestone payment to begin a late stage study to treat ulcerative colitis and Crohn's disease.
The company TEVA.N said it earned 96 cents per diluted share, excluding one-time items, in the October to December quarter, up from 71 cents a share a year earlier. Revenue was up 11% in dollar terms at $4.71 billion.
Analysts had forecast earnings of 64 cents per share ex-items for the Israel-based company on revenue of $4.32 billion, LSEG I/B/E/S data showed.
The group estimated 2026 revenue estimate of $16.4-$16.8 billion, versus $17.3 billion in 2025. It projects adjusted EPS forecast of $2.57-$2.77, compared with $2.93 in 2025.
Related Articles
Coca Cola (KO) Q4 Earnings Preview: Look for the Upside in the AI Initiatives, not in the Revenue and the EPS
Coca-Cola (KO) enters its fourth-quarter 2025 earnings call tomorrow with significant momentum. However, a fundamental shift is occurring.
Warsh’s Fed Era Signals a Death Knell for QE, Jolting the $30 Trillion Treasury Market
With Warsh’s nomination, his past proposals for governing the Federal Reserve are being brought to the forefront. A central issue is the formulation of a new "1951 Accord" to restructure the relationship between the Fed and the Treasury. Analysts suggest such a move could impact the $30 trillion Tre
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
